GlassScriptPhysician profile
Christine A Powell
NPI 1639228141
$32,894.49
in general payments reported to CMS, 2019-2025
57 companies · $5,411 in 2025
The $5,411 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,862 · 2020: $1,291 · 2021: $4,878 · 2022: $4,945 · 2023: $8,276 · 2024: $5,232 · 2025: $5,411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Consulting Fee: $2,835 · Education: $381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,702.53 |
| Consulting Fee | $2,835.00 |
| Education | $381.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $4,390.61 | 2019-2025 | Prolia, Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $2,757.59 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $2,489.41 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Glaxosmithkline, LLC. | $2,485.72 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $2,207.64 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $2,131.76 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $1,450.33 | 2021 | |
| Novo Nordisk INC | $1,369.68 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Axsome Therapeutics, INC. | $1,197.75 | 2022-2025 | Auvelity, Sunosi, Symbravo |
| Supernus Pharmaceuticals, INC. | $1,079.00 | 2019-2025 | Qelbree, Qelbree |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,032.34 | 2019-2025 | Jardiance |
| Pfizer INC. | $1,024.47 | 2019-2025 | |
| Lilly USA, LLC | $923.01 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $901.94 | 2023-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $896.96 | 2019-2023 | Belsomra, Steglatro |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Powell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.